MedTrace Logo

Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

NCT01983735 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-11-14

No results posted yet for this study

Summary

The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Conditions

Interventions

DRUG

TELMINUVO Tab. (80/2.5mg)

* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks. * With the others investigation product placebo 1 tab QD 2 weeks.

DRUG

TELMINUVO Tab. (80/5mg)

* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks. * With the others investigation product placebo 1 tab QD 6 weeks.

DRUG

S-amlodipine 2.5mg

* S-amlodipine 2.5mg QD 2 weeks * With the others investigation product placebo 1 tab QD 2 weeks.

DRUG

S-amlodipine 5mg

* S-amlodipine 5mg QD 6weeks * With the others investigation product placebo 1 tab QD 6 weeks.

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983735 on ClinicalTrials.gov